Summit Therapeutics Inc. Dividend History (SMMT)
Summit Therapeutics Inc. does not pay dividends currently 😔
They might in the future, check back soon!
About Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of antibiotics for the treatment of infectious diseases, particularly those caused by multi-drug resistant bacteria. Founded in 2003, the company's mission is to pioneer new classes of antibiotics that address significant unmet medical needs. As of 2023, the CEO is Robert W. Duggan, a seasoned entrepreneur with extensive experience in driving business growth within the pharmaceuticals sector. Summit Therapeutics is known for its innovative pipeline of antibiotic candidates and its commitment to combating the global antibiotic resistance crisis. While exact revenue figures may vary year to year, the company actively engages in partnerships and collaborations to bolster its research and development efforts. Through its groundbreaking work, Summit Therapeutics aims to make a meaningful impact on global health.
Summit Therapeutics stock surged nearly 6% after Jefferies initiated coverage with a buy recommendation and a $31 price target, citing the promising results of the company's cancer drug ivonescimab in clinical trials.
The Motley Fool · Published on Sat Dec 07 2024Billionaire Ken Griffin's Citadel fund has sold 91% of its Palantir shares and started a new position in Summit Therapeutics, a biotech stock that Wall Street expects to surge 139% higher.
The Motley Fool · Published on Mon Dec 02 2024